Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) CEO Justin B. Klee sold 18,589 shares of the business’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $3.20, for a total transaction of $59,484.80. Following the sale, the chief executive officer now directly owns 3,120,569 shares in the company, valued at $9,985,820.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Amylyx Pharmaceuticals Stock Down 1.0 %
Shares of AMLX traded down $0.03 during mid-day trading on Wednesday, reaching $3.03. The company had a trading volume of 738,408 shares, compared to its average volume of 2,086,326. The stock has a market capitalization of $206.06 million, a P/E ratio of -2.83 and a beta of -0.62. Amylyx Pharmaceuticals, Inc. has a 52-week low of $1.58 and a 52-week high of $19.95. The stock has a 50 day moving average of $2.37 and a two-hundred day moving average of $2.15.
Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.35). Amylyx Pharmaceuticals had a negative return on equity of 15.51% and a negative net margin of 17.86%. The business had revenue of ($1.02) million during the quarter, compared to analyst estimates of $18.83 million. During the same period in the previous year, the company posted $0.31 EPS. On average, sell-side analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.27 earnings per share for the current year.
Institutional Investors Weigh In On Amylyx Pharmaceuticals
Analysts Set New Price Targets
Several research firms have weighed in on AMLX. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Amylyx Pharmaceuticals in a research note on Wednesday, July 10th. The Goldman Sachs Group upped their target price on Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the company a “neutral” rating in a research report on Friday, July 12th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $17.60.
Read Our Latest Stock Analysis on AMLX
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.
Further Reading
- Five stocks we like better than Amylyx Pharmaceuticals
- 3 Small Caps With Big Return Potential
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- Using the MarketBeat Dividend Yield Calculator
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.